

Gilead Sciences Ukraine EFPIA Report 2024

Date of publication: 30/06/2025

	Full Name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	Unique country identifier OPTIONAL	Donations and Grants to HCOs (Ar. 14.3.3)	Costs associated with the Events (Sub-clause. 14.3.3)			Fees for service and consultancy (Ar. 14.3.2 i 14.3.3)			TOTAL OPTIONAL
	(Ar. 14.1.1)	(Ar.. 14.3)		(Ar. 14.3)	(Ar.. 14.3)		Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		
H C P S	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
	OTHER, NOT INCLUDED ABOVE-where information cannot be disclosed on an individual basis for legal reasons												
	Aggregate amount attributable to transfers of value to such Recipients - Ar.14.3.4												
	Number of Recipients in aggregate disclosure - Ar.14.3.4												
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Ar.14.3.4												
H C O S	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
	OTHER, NOT INCLUDED ABOVE-where information cannot be disclosed on an individual basis for legal reasons												
	Aggregate amount attributable to transfers of value to such Recipients - Ar.14.3.4												
	Number of Recipients in aggregate disclosure Ar.14.3.4												
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Ar.14.3.4												
R & D	AGGREGATE DISCLOSURE												
	Transfers of Value re Research & Development as defined - Article 14.3.6											53,794.35 €	